SITE006-0105

SITE006 (GBR) › SITE006-0105

SITE006-0105

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2026-01-10

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 170); relationship: NOT RELATED

moderate assessed

Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 109); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 18); relationship: RELATED

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.